The Bancorp Bank Inc (NASDAQ:TBBK) a wholly owned subsidiary of The Bancorp, Inc., (Nasdaq: TBBK) entered into a Stipulation and Consent to the Issuance of a Consent Order (the “Order”) with the Federal Deposit Insurance Corporation (the “FDIC”) which became effective on June 5, 2014. The Bank took this action without admitting or denying any charges of unsafe or unsound banking practices or violations of law or regulation relating to weaknesses in the Bank’s Bank Secrecy Act (“BSA”) Compliance Program. Bancorp Inc (NASDAQ:TBBK) net profit margin is 16.30% and weekly performance is 3.12%. On last trading day company shares ended up $16.20. Analysts mean target price for the company is $19.25. Bancorp Inc (NASDAQ:TBBK) distance from 50-day simple moving average (SMA50) is -2.99%.
On June 9, Receptos, Inc. (NASDAQ:RCPT) announced that the Phase 2 portion of the RADIANCE trial of its selective S1P1 receptor modulator, RPC1063, in relapsing multiple sclerosis (RMS) met the primary endpoint, reduction in MRI brain lesion activity. The overall safety profile of RPC1063 was consistent with the results of prior trials, and continues to support the differentiation of the drug candidate against other oral agents for treatment of RMS on the market or in clinical development. Receptos Inc (NASDAQ:RCPT) shares advanced 36.78% in last trading session and ended the day on $39.94. Its return on assets is -61.10%. Receptos Inc (NASDAQ:RCPT) quarterly performance is -19.43 %.
At 10:00 a.m. EDT, Wednesday, June 4, 2014, John A. Scarlett, M.D., President and Chief Executive Officer of Geron Corporation (NASDAQ:GERN) will present a company overview at the Jefferies 2014 Global Healthcare Conference in New York, New York. The slides accompanying the presentation, together with a slide setting forth certain cautionary language intended to qualify the forward-looking statements included in the presentation, are furnished as Exhibit 99.1 to this Current Report and are incorporated herein by reference. The slides will also be made available in the “Investor Relations” section of Geron’s website, located at www.geron.com. Geron Corporation (NASDAQ:GERN) shares moved up 9.81% in last trading session and was closed at $2.35, while trading in range of $2.05- $2.18. Geron Corporation (NASDAQ:GERN) year to date (YTD) performance is -50.42%.
Dendreon Corporation (NASDAQ:DNDN) has been given an average recommendation of “Hold” by the nineteen analysts that are presently covering the stock, Analyst RN reports. Seven analysts have rated the stock with a sell rating, ten have given a hold rating and one has issued a buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $2.83. Dendreon Corporation (NASDAQ:DNDN) ended the last trading day at $2.08. Company weekly volatility is calculated as 5.74% and price to cash ratio as 2.14. Dendreon Corporation (NASDAQ:DNDN) showed a positive weekly performance of 7.22%.
Himax Technologies, Inc. (ADR) (NASDAQ:HIMX) a supplier and fabless manufacturer of advanced display drivers and other semiconductor products, declared a cash dividend of 27 cents per ADS, or 13.5 cents per ordinary share, for the year of 2013. The cash dividend is expected to be paid on July 23, 2014 to all the shareholders of record as of July 11, 2014. The ADS book will be closed for issuance and cancellation from July 4, 2014 to July 11, 2014. Ex-dividend date is two trading days prior to the record date. Himax Technologies, Inc. (ADR) (NASDAQ:HIMX) net profit margin is 8.00% and weekly performance is 6.90%. On last trading day company shares ended up $6.66. Analysts mean target price for the company is $9.78. Himax Technologies, Inc. (ADR) (NASDAQ:HIMX) distance from 50-day simple moving average (SMA50) is -21.07%.
Leave a Reply